Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 07, 2022

BUY
$0.51 - $117.79 $27,985 - $6.46 Million
54,874 New
54,874 $24,000
Q2 2022

Aug 09, 2022

SELL
$0.4 - $0.75 $8,842 - $16,579
-22,106 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$0.61 - $0.75 $13,484 - $16,579
22,106 New
22,106 $16,000
Q4 2021

Feb 17, 2022

SELL
$0.66 - $1.1 $34,285 - $57,141
-51,947 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$0.9 - $1.31 $25,846 - $37,620
-28,718 Reduced 35.6%
51,947 $55,000
Q2 2021

Sep 17, 2021

SELL
$0.87 - $1.58 $41,238 - $74,893
-47,401 Reduced 37.01%
80,665 $90,000
Q1 2021

May 19, 2021

BUY
$1.31 - $2.35 $110,002 - $197,331
83,971 Added 190.43%
128,066 $196,000
Q4 2020

Feb 24, 2021

SELL
$1.26 - $2.75 $951 - $2,076
-755 Reduced 1.68%
44,095 $56,000
Q3 2020

Dec 11, 2020

BUY
$1.7 - $2.61 $4,715 - $7,240
2,774 Added 6.59%
44,850 $80,000
Q2 2020

Aug 07, 2020

BUY
$1.36 - $2.26 $57,223 - $95,091
42,076 New
42,076 $89,000
Q4 2019

Feb 04, 2020

SELL
$0.87 - $1.45 $9,370 - $15,617
-10,771 Closed
0 $0
Q3 2019

Nov 20, 2019

BUY
$0.72 - $1.31 $7,755 - $14,110
10,771 New
10,771 $10,000
Q4 2018

Jan 16, 2019

SELL
$0.85 - $2.1 $52,646 - $130,067
-61,937 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$0.98 - $1.97 $29,330 - $58,960
29,929 Added 93.5%
61,937 $116,000
Q1 2018

May 14, 2018

BUY
$1.92 - $2.4 $12,481 - $15,602
6,501 Added 25.49%
32,008 $62,000
Q4 2017

Feb 09, 2018

BUY
$1.84 - $2.32 $46,932 - $59,176
25,507
25,507 $57,000

Others Institutions Holding SNGX

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About SOLIGENIX, INC.


  • Ticker SNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,105,200
  • Market Cap $125M
  • Description
  • Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has c...
More about SNGX
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.